secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001396814-25-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira BioSciences: 2024 record rev $701M, GAAP net loss $99.6M on $163M impairment; FY2025 rev guide $725M-$765M
--------------------------------------------------------------------------------

- Q4 2024 rev $187.3M (+3% YoY); full-year rev $701.0M (+4%); EXPAREL $549M, ZILRETTA $118M, iovera $22.8M.
- Full-year GAAP net loss $99.6M ($2.15 loss/share) includes $163.2M goodwill impairment; adjusted EBITDA $223.9M (+4%).
- Non-GAAP net income $157.7M ($3.20 diluted); Q4 non-GAAP net income $44.3M ($0.91 diluted).
- Acquired remaining 81% of GQ Bio for ~$32M net; adds genetic medicine platform, eliminates future milestones.
- FY2025 guidance: rev $725-765M, non-GAAP gross margin 76-78%, R&D $90-105M, SG&A $290-320M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000039/0001396814-25-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000039/pcrx-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001396814-25-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer